Search results
Tiziana eyes orphan drug designation for multiple sclerosis treatment
Proactive Investors· 2 days agoTiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted...
9 celebrities with multiple sclerosis who have opened up about the disease
Yahoo Canada Style· 5 days ago“I knew nothing about the disease, to be honest. I fortunately had a doctor who told me right away...
Diagnosing Multiple Sclerosis: 5 Things to Know
Medscape· 6 days agoIn the United States, nearly 1 million people are living with multiple sclerosis (MS), an immune-mediated inflammatory disease that causes demyelination...
This Mother's Day, I'm celebrating the fact that I can bake with my kid again. Not long ago, that...
INSIDER via Yahoo News· 2 days agoReceiving treatment for multiple sclerosis allowed Lindsay Karp (not pictured) to start baking with...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
WRBL Columbus· 12 hours agoKyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, ...
Ocrevus and interactions: Other drugs, alcohol, and more
Medical News Today· 1 day agoOcrevus (ocrelizumab) is a brand-name injection that’s prescribed for certain forms of multiple ...
Sketchy stem-cell treatments in Mexico led to drug-resistant infections
Live Science via Yahoo News· 1 day agoThe injections were reportedly intended to treat the autoimmune disease multiple sclerosis, for...
Earnings call: Immunic outlines progress and financials for Q1 2024
Investing.com· 6 days agoImmunic, Inc. (NASDAQ: IMUX ) reported a loss in the first quarter of 2024 but showcased progress in...
Immunic advances ‘potentially groundbreaking’ MS therapy vidofludimus calcium during Q1
Proactive Investors· 7 days agoImmunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset,...
Undervalued by 28%, This Stock Is a Buy for Patient Investors
Morningstar· 7 days agoBiogen BIIB is having a tough year: Its shares are down 15% through early May. The wide-moat...